UNOVARTIS

SANDOSTATIN LAR - Administration video - HCP

Prescribing information

Image



Image



How to administer and prepare SANDOSTATIN® LAR® (octreotide acetate)



Mixing and Administration

Adverse events should be reported. Reporting forms and information can be found at <u>www.mhra.gov.uk/yellowcard</u>. Adverse events should also be reported to Novartis via <u>uk patientsafety@novartis.com</u> or online through the pharmacovigilance intake (PVI) tool at <u>www.novartis.com/report</u> If you have a question about the product, please contact Medical Information on 01276 698370 or by email at <u>medinfouk@novartis.com</u>



UK | February 2025 | FA-11214504

Adverse events should be reported. Reporting forms and information can be found at <u>www.mhra.gov.uk/yellowcard</u>. Adverse events should also be reported to Novartis online

through the pharmacovigilance intake (PVI) tool at <u>www.novartis.com/report</u>, or alternatively email <u>medinfo.uk@novartis.com</u> or call 01276 698370.

Source URL:

https://www.pro.novartis.com/uk-en/medicines/oncology/sandostatin-lar/administration-vide o